MétaCan
Menu
Back to cohort
Record W4384826415 · doi:10.26685/urncst.489

Psilocybin Therapy for Major Depressive Disorder: A Systematic Review

2023· review· en· W4384826415 on OpenAlexafffund
Kaden Venugopal

Bibliographic record

VenueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2023
Typereview
Languageen
FieldPsychology
TopicPsychedelics and Drug Studies
Canadian institutionsUniversity of Ottawa
FundersUniversity of British ColumbiaYork UniversityUniversity of Ottawa
KeywordsPsilocybinPsychologyPeer reviewMedical educationLibrary scienceMedicinePsychotherapistPolitical sciencePsychiatryHallucinogenComputer science

Abstract

fetched live from OpenAlex

Introduction: Major depressive disorder (MDD) is a prevalent and complex mood disorder. Its psychotherapies often involve delayed treatment-response times, while its pharmacotherapies can cause unwanted side effects. In recent years, there has been a resurgence in psychedelic research with a specific interest in the potential of psilocybin for treating MDD. Therefore, this systematic review was performed to evaluate the effectiveness of psilocybin therapy at moderate (15±5 mg/70 kg) to high (25 ± 5 mg/70 kg) doses in the psychiatric treatment of MDD. Methods: The review included a literature search using PubMed (Medline), SCOPUS, Web of Science, and Medline (Ovid) databases from January 1, 2013, to February 28, 2023. Seven studies were included following the inclusion and exclusion criteria (e.g., moderate to high dosing psilocybin treatment, peer-reviewed, moderate to severe depression, control/delayed treatment groups, and non-directive therapy during psilocybin sessions). Studies were excluded using PRISMA guidelines and appraised using the Critical Appraisal Skills Programme checklists. Results: The primary outcomes assessed included changes in depression scores on validated diagnostic tools and secondary outcomes that supported depression remission (e.g., improved well-being and rumination scores, and decreased anxiety scores). Psilocybin was found to reduce depression symptoms in moderate single-dose contexts and have minimal reported side effects at high doses. A positive relationship was observed between the quality of psilocybin-induced experiences and the reduction in depressive symptoms. Additionally, a dose-response relationship was found between moderate (15±5 mg/70 kg) and high-dose psilocybin (25 ± 5 mg/70 kg), with greater improvements generally seen in higher dose conditions. Discussion: This review suggests that psilocybin can be an effective treatment option for MDD. Psilocybin shows meaningful improvements in depression scores with the potential to treat psychiatric conditions concurrent to depression. The non-directive therapy approach during high-dose sessions enabled unique psychedelic and personal experiences, potentially allowing more profound and individualized therapy. Reported side effects were minimal, and suggestions for future studies are provided. Conclusion: Psilocybin therapy was found to reduce depression levels and improve secondary outcomes that support depression remission, indicating efficacy for MDD and other depressive conditions. Despite seeming promising, further research is required before introducing PAP options to...

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.018
metaresearch head score (Gemma)0.006
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Science and technology studies, Research integrity
Consensus categoriesScience and technology studies
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.856
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0180.006
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0030.000
Bibliometrics0.0020.005
Science and technology studies0.0010.004
Scholarly communication0.0000.000
Open science0.0020.001
Research integrity0.0010.004
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.210
GPT teacher head0.549
Teacher spread0.339 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designOther design
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) JournalSame topicPsychedelics and Drug StudiesFrench-language works237,207